Welcome to the G-FINDER survey
The G-FINDER survey tracks annual investment into R&D for new products and technologies to address priority global health challenges. This includes basic research and the development of new drugs, vaccines, diagnostics and other tools for global health priorities that disproportionately affect people in low- and middle-income countries, including neglected diseases (NDs), emerging infectious diseases (EIDs) and sexual and reproductive health (SRH) issues.
As part of the ongoing evolution and improvement of the G-FINDER project, we have made the following changes to the survey scope:
- Histoplasmosis and scabies have been added to the G-FINDER scope, including basic research, drugs and diagnostics (the scope for scabies basic research investments is restricted)
- Enterotoxigenic E. coli (ETEC) and rotavirus have been expanded to include basic research targeting LMICs
- The restrictions on hepatitis C vaccine R&D have been removed
- Lassa fever and Other arenaviral diseases have been expanded to include reservoir-targeted vaccines
- On-demand contraception and Multipurpose prevention technologies (MPTs) have been expanded to include biologics
If you provided FY2020 data for COVID-19 basic research and product development in last year’s survey, you will find this data pre-populated in the relevant financial tables in this year’s survey. You are able to make changes to these grants in the usual way.
Before you start the survey
Is your data ready to enter?
- Arrange data at grant level
- Collate funds disbursed
- Collate funds received
- Sort data by disease or health issue